梁璐，女，广州医科大学药学院，广东省分子靶标与临床药理学重点实验室，副教授，硕士生导师。2017年毕业于香港科技大学，获博士学位。香港科技大学广州校友会副会长，广东省药理学会第二届药物筛选与评价专业委员会委员，广东省心血管药理专委会委员，《Chinese Medicine》学报青年编委。目前主要从事肺癌的发生和发展等方面的研究，开展表观遗传药理学在肺癌心脏病学相关领域的研究。同时，筛选具有表观遗传调控作用的抗肺癌的天然产物。以第一作者在国际知名杂志Molecular Cancer (IF > 40), Acta Pharmaceutica Sinica B (IF > 10), Acta Pharmacologica Sinica, Materials Science & Engineering C, Frontiers in Chemistry, Chemico-Biological Interactions, Toxicology Letters, Journal of Agricultural and Food Chemistry, Phytotherapy Research等发表文章。主持国家自然科学基金青年项目，广东省中药局项目，广州市科技局等项目。同时主持广州市教育局、广州市教育研究院教改项目以及校级教改项目等。
联系邮箱：luliang20100224@126.com
主要科研项目
1、国家自然科学基金青年项目，Hippo信号通路效应蛋白YAP1介导的巨噬细胞极化在急性肺损伤中的作用及机制研究，主持。
2、国家自然科学基金青年项目，细胞膜仿生纳米级联反应器的构建及其在肿瘤靶向协同治疗中的应用，主要参与人。
3、广东省中药局项目，地钱素C通过调控纤毛依赖的Hedgehog/Gli-3信号通路干预非小细胞肺癌侵袭转移的机制研究，主持。
4、广州市教育局项目，科教融合为导向的药学卓越创新人才实验班, 主持。
5、广州市教育研究院项目，粤港澳大湾区产学研融合创新药学人才育人机制研究，主持，已结题。
6、广州医科大学项目，药学专业产学研用协同育人机制研究，主持。
7、广州医科大学项目，纤毛形成基因OFD1对纤毛介导的非小细胞肺癌转移的干预作用机制，主持。
主要论文及著作（代表性）
(1) Lu Liang#; Huiyu Cen#; Jionghua Huang#; Aiping Qin#; Wenyan Xu; Siran Wang; Zhijun Chen; Lin Tan; Qiqi Zhang; Xiyong Yu*; Xin Yang*; Lingmin Zhang*; The reversion of DNA methylation‑induced miRNA silence via biomimetic nanoparticles‑mediated gene delivery for efficient lung adenocarcinoma therapy, Molecular Cancer, 2022, 21(1): 186. (IF = 41.444)
(2) Lu Liang#; Wenyan Xu#; Ao Shen#; Huiyu Cen; Zhijun Chen; Lin Tan; Lingmin Zhang; Yu Zhang; Jijun Fu; Aiping Qin; Xueping Lei; Songpei Li; Yuyan Qin*; Jionghua Huang*; Xiyong Yu*; Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9, Acta Pharmacologica Sinica, 2022, 43(11): 2946-2955. (IF = 7.169)
(3) Guining Feng#; Xiaotao Huang#; Xinlin Jiang#; Tingwei Deng; Qiuxia Li; Jiexia Li; Qianni Wu; Songpei Li; Xianqiang Sun; Yugang Huang; Aiping Qin*; Lu Liang*; Jijun Fu*; The Antibacterial Effects of Supermolecular Nano-Carriers by Combination of Silver and Photodynamic Therapy, Frontiers in Chemistry, 2021, 9: 666408. (IF = 5.545)
(4) Xin Li#; Wenxia Lv#; Weiqi Yang#; Yinfeng Guo; Jianwen Huang; Wenyi Liang; Yugang Huang; Aiping Qin; Xingmei Deng; Xufeng Li; Mianrong Chen; Hainan Yang*; Lu Liang*; Lingran Du*; Poly (hydroxyethyl methacrylate-acrylic acid) microspheres loaded with magnetically responsive Fe3O4 nanoparticles for arterial embolization, drug loading and MRI detection, Journal of Drug Delivery Science and Technology, 2022, 79: 103993. (IF = 5.062)
(5) Yuyan Qin#; Songpei Li#; Aiping Qin#; Yinshan Lin; Jinxian Ye; Yingying Huang; Jianglin Wang; Lu Liang*; Xiyong Yu*; Lingmin Zhang*; Targeted and Infarcted Microenvironment-Responsive Peptide Therapeutics to Reverse Cardiac Remodeling, Advanced Therapeutics, 2022 Oct 20. Online ahead of print. (IF = 5.003)
(6) Lu Liang#; Jijun Fu#; Siran Wang#; Huiyu Cen; Lingmin Zhang; Safur Rehman Mandukhail; Lingran Du; Qianni Wu; Peiquan Zhang*; Xiyong Yu*; MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1, Acta Pharmaceutica Sinica B, 2020, 10: 1036-46. (IF = 14.903)
(7) Lu Liang; Aftab Amin; Wing-Yan Cheung; Rui Xu; Rujian Yu; Jinshan Tang; Xinsheng Yao; Chun Liang*; Parameritannin A-2 from Urceola huaitingii enhances doxorubicin-induced mitochondria-dependent apoptosis by inhibiting the PI3K/Akt, ERK1/2 and p38 pathways in gastric cancer cells, Chemico-Biological Interactions, 2020, 316: 108924. (IF = 5.168)
(8) Minyan Wei#; Xueping Lei#; Jingjing Fu#; Mingyue Chen; Jiexia Li; Xiyong Yu; Yinlei Lin; Jingping Liu; Lingran Du; Xin Li; Yu Zhang; Yingling Miao; Yugang Huang*; Lu Liang*; Jijun Fu; The use of amphiphilic copolymer in the solid dispersion formulation of nimodipine to inhibit drug crystallization in the release media: Combining nano-drug delivery system with solid preparations, Mater Sci Eng C Mater Biol Appl, 2020, 111: 110836. (IF = 8.457)
(9) Lu Liang#; Meng Luo#; Yujie Fu*; Yuangang Zu; Wei Wang; Chengbo Gu; Chunjian Zhao; Chunying Li; Thomas Efferth. Cajaninstilbene acid (CSA) exerts cytoprotective effects against oxidative stress through the Nrf2-dependent antioxidant pathway, Toxicology Letters, 2013, 219: 254-61. (IF = 4.271)
(10) Lu Liang; Chang Gao; Meng Luo; Wei Wang; Chunjian Zhao; Chunying Li; Yuangang Zu; Thomas Efferth; Yujie Fu*; Dihydroquercetin (DHQ) induce HO-1 and NQO1 expression against oxidative stress through the Nrf2-dependent antioxidant pathway, Journal of Agricultural and Food Chemistry, 2013, 61: 2755-61. (IF = 5.895)
(11) Lu Liang#; Meng Luo#; Chunjian Zhao; Wei Wang; Chengbo Gu; Yuangang Zu; Yujie Fu*; The phytoestrogen activity of Pigeon Pea roots is associated with the activation of eatrogen receptor α dependent signaling pathway in human prostate cancer cell, Phytotherapy Research, 2013, 27: 1834-41. (IF = 6.388)
中文核心期刊论文
(1) 梁璐，蔡晓彤，岑慧裕，徐文艳，洪超，谭霖，余细勇*. 甘木通活性化合物的抗氧化活性及对H2O2诱导的H9C2心肌细胞损伤的保护作用, 中国药理学通报，2021 Nov；37(11):1530-1535.
(2) 梁璐，岑慧裕，洪超，蔡晓彤，林忠晓，杜玲然，余细勇*. MiR-142-3p靶向 HMGB1逆转乳腺癌细胞MCF-7对阿霉素的耐药性，中国药理学通报，2020 Feb；36(2):191-197.
(3) 徐文艳，岑慧裕，余细勇，梁璐*. 天然产物抗肿瘤表观遗传调控作用的研究状况，中国临床药理学志，2022 Oct；38 (20):2502-2505.
教改论文
(1) 梁璐，汪园，张羽，雷雪萍，余细勇*. 药学拔尖创新人才培养模式的探讨——以广州医科大学为例. 广东化工, 2021;16(48):302-304.
(2) 梁璐，杜玲然，林忠晓，王声，余细勇*. 药学本科专业产学研协同育人的探索. 广州医科大学学报. 2019;47(6):116-121.
(3) 梁璐，李松沛，杜玲然，余细勇. 药学卓越班学生培养方法论——以广州医科大学药学院大学生为例. 新课程研究, 2019;6(14):109-110.
